.jpg)
METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF ALZHEIMER´S DISEASE
US18/552,099
This Luminex xMap based-technology would allow Alzheimer´s disease (AD) diagnosis at a very early stage of the disease through the simultaneous analysis of the levels of 27 CSF biomarkers. This method, besides predict the risk to develop AD, would permit to track the progression of the disease potentially allowing to test the efficacy of new therapies.
This technology is addressed to have a potential clinical application since it could be used routinely to diagnose and monitor AD progression at low cost. Among its technical advantages, it is important to mention the high sensitivity and reliability of this technology and the reduced volume of CSF necessary for the assay. Additionally, once developed, the cost for this bioarray would be approximately 350 euros per patient, which could be compatible with a conventional use in the clinic.